Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REGN668 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | - |
| Cohort 2 | EXPERIMENTAL | - |
| Cohort 3 | EXPERIMENTAL | - |
| Dose 1 | EXPERIMENTAL | (3:1, active:placebo) |
| Dose 2 | EXPERIMENTAL | (3:1, active:placebo) |
| Dose 3 | EXPERIMENTAL | (3:1, active:placebo) |
| Dose 4 | EXPERIMENTAL | (3:1, active:placebo) |
| Name | Type | Description |
|---|---|---|
| REGN668 | BIOLOGICAL | Dose 1: REGN668 or placebo |
Inclusion Criteria: * Clinical diagnosis of atopic dermatitis that has been present for at least 3 years before the screening visit * Investigator's Global Assessment (IGA) score of \>/= 3 at the screening and baseline visits * \>/= 15% body surface area (BSA) of AD involvement at the screening and...
Top 20 of 25 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 9 | PHASE3 | Upadacitinib, corticosteroids |
| Pfizer Inc. | PFE | 11 | PHASE3 | Abrocitinib |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Lebrikizumab, Corticosteroid |
| Sanofi SA Sponsored ADR | SNY | 13 | PHASE3 | Amlitelimab |
| Regeneron Pharmaceuticals, Inc. | REGN | 4 | PHASE3 | Dupilumab |
| Incyte Corporation | INCY | 3 | PHASE3 | Ruxolitinib, Vehicle |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof, 1%, Vehicle |
| Apogee Therapeutics, Inc. | APGE | 3 | PHASE2 | APG777 |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | GIA632 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Corvus Pharmaceuticals, Inc. | CRVS | 1 | PHASE2 | Soquelitinib |
| Nektar Therapeutics | NKTR | 1 | PHASE2 | Rezpegaldesleukin |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE2 | Barzolvolimab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
| Sunshine Biopharma Incorporated | SBFM | 3 | PHASE3 | 611, corticosteroid |
| Aclaris Therapeutics, Inc. | ACRS | 1 | PHASE2 | ATI-045 |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | ADX-914 |
| Turn Therapeutics Inc. | TTRX | 1 | PHASE2 | GX-03 |
| Arcutis Biotherapeutics Inc | ARQT | 1 | PHASE1 | ARQ-234 |
REGN668 is an investigational monoclonal antibody being studied for use in healthy volunteers and in patients with atopic dermatitis, a form of dermatitis. It is in Phase 1 clinical development and is not yet approved by the FDA.
REGN668 is being developed by Regeneron Pharmaceuticals, Inc., which trades under the ticker symbol REGN on the NASDAQ. The company is conducting clinical trials to evaluate the safety and tolerability of this investigational drug.
REGN668 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA and is still being studied in clinical trials to assess its safety and tolerability in humans.
REGN668 has been studied in two completed Phase 1 clinical trials. The first, NCT01015027, was an ascending dose study in healthy volunteers. The second, NCT01259323, was a sequential ascending dose study in patients with atopic dermatitis. Both trials were conducted in the United States.
Yes, REGN668 is also known as SAR231893. Both names refer to the same investigational monoclonal antibody being developed by Regeneron Pharmaceuticals. Clinical trials have used both names to describe the drug.